FCM
GILD icon

Fairbanks Capital Management’s Gilead Sciences GILD Stock Holding History

Fairbanks Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,393
Closed -$201K – 52
2024
Q3 		$201K Sell
2,393
-3,717
-61% -$284K 0.13% 51
2024
Q2 		$419K Hold
6,110
– – 0.28% 52
2024
Q1 		$448K Sell
6,110
-3,060
-33% -$235K 0.31% 51
2023
Q4 		$743K Sell
9,170
-1,237
-12% -$96.3K 0.53% 44
2023
Q3 		$780K Sell
10,407
-55
-0.5% -$4.23K 0.66% 40
2023
Q2 		$806K Sell
10,462
-1,575
-13% -$126K 0.63% 43
2023
Q1 		$999K Sell
12,037
-460
-4% -$38.1K 0.79% 38
2022
Q4 		$1.07M Sell
12,497
-360
-3% -$28.5K 0.95% 35
2022
Q3 		$793K Sell
12,857
-1,644
-11% -$104K 0.74% 40
2022
Q2 		$896K Sell
14,501
-639
-4% -$39.6K 0.78% 38
2022
Q1 		$900K Sell
15,140
-1,032
-6% -$66K 0.67% 42
2021
Q4 		$1.17M Hold
16,172
– – 0.85% 39
2021
Q3 		$1.13M Sell
16,172
-9,767
-38% -$686K 0.92% 37
2021
Q2 		$1.79M Sell
25,939
-2,789
-10% -$186K 1.41% 26
2021
Q1 		$1.86M Buy
28,728
+92
+0.3% +$5.93K 1.52% 22
2020
Q4 		$1.67M Sell
28,636
-7
-0% -$422 1.49% 23
2020
Q3 		$1.81M Sell
28,643
-4,263
-13% -$296K 1.81% 19
2020
Q2 		$2.24M Buy
32,906
+414
+1% +$31.7K 2.2% 15
2020
Q1 		$2.43M Sell
32,492
-6,144
-16% -$425K 3.18% 10
2019
Q4 		$2.51M Sell
38,636
-12,558
-25% -$818K 2.59% 14
2019
Q3 		$3.25M Sell
51,194
-1,336
-3% -$87.3K 3.34% 11
2019
Q2 		$3.55M Sell
52,530
-1,365
-3% -$89.8K 3.78% 11
2019
Q1 		$3.5M Sell
53,895
-144
-0.3% -$9.57K 3.58% 11
2018
Q4 		$3.38M Buy
54,039
+8,808
+19% +$616K 3.74% 12
2018
Q3 		$3.49M Buy
45,231
+8,876
+24% +$670K 3.49% 9
2018
Q2 		$2.58M Buy
36,355
+321
+0.9% +$22.7K 3.01% 9
2018
Q1 		$2.72M Sell
36,034
-7,106
-16% -$565K 2.74% 9
2017
Q4 		$3.09M Sell
43,140
-1,503
-3% -$114K 2.84% 9
2017
Q3 		$3.62M Buy
+44,643
New +$3.41M 3.51% 7

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fairbanks Capital Management's GILD Position: Q4 2024 in Review

Fairbanks Capital Management sold out of Gilead Sciences (GILD) in Q4 2024, closing a stake of 2,393 shares — an estimated $201K sold.

Fairbanks Capital Management first reported a position in GILD in Q3 2017 and held it in 29 quarters. The position peaked at $3.62M in Q3 2017. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

  • Fairbanks Capital Management reported no remaining Gilead Sciences position as of Q4 2024 after selling out during the quarter.
  • Fairbanks Capital Management sold 2,393 Gilead Sciences shares in Q4 2024, an estimated $201K.
  • Fairbanks Capital Management first reported a position in Gilead Sciences in Q3 2017 and held it in 29 quarters.
  • Fairbanks Capital Management's Gilead Sciences position peaked at $3.62M in Q3 2017.
  • 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Fairbanks Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.